Is there an association between choice of thymidine analogue and lipid abnormalities in HIV-1 infected patients?
Matthews G, Moyle G, Mandalia S, Bower M, Nelson M, Gazzard BG; International Conference on AIDS. Int Conf AIDS. 2000 Jul 9-14; 13: abstract no. WePeB4241. G. Matthews, Chelsea and Westminster Hospital, London, United Kingdom, Tel.: +44 0181 746 5610, Fax: +44 0181 746 8537, E-mail: sandra.mead@chelwest.org Aim: To determine any significant link between the use of specific thymidine analogues and hyperlipidaemia Method: Database analysis of all patients taking D4T or AZT in 1st line therapy with an NNRTI and having at least 1 cholesterol/triglyceride (TG) measurement. PI-containing regimes were excluded. Results: 135 patients identified: 97 on D4T, 39 on AZT. 66 patients prescribed efavirenz and 69 nevirapine. 29% of patients had cholesterol values > 5.6 mmol and 26% TG > 2.2 mmol. Median duration of therapy was 132 days. 65% of patients had HIV VL > 50 c/ml – no difference between groups. In multivariate analysis only age and TG level were significant independent predictors of raised
Related Questions
- Is there an association with constitutional structural chromosomal abnormalities and hematologic neoplastic process?
- Is there an association between choice of thymidine analogue and lipid abnormalities in HIV-1 infected patients?
- What is American Diabetes Association’s message to patients in light of the this announcement?
